Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was...
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained...
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific...
HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...
HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.